Ameriprise Financial Inc. Raises Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Ameriprise Financial Inc. raised its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 54.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,706 shares of the biopharmaceutical company’s stock after acquiring an additional 8,326 shares during the period. Ameriprise Financial Inc.’s holdings in Revance Therapeutics were worth $72,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. MetLife Investment Management LLC raised its holdings in shares of Revance Therapeutics by 7.5% during the 4th quarter. MetLife Investment Management LLC now owns 60,514 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 4,235 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Revance Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock worth $2,424,000 after acquiring an additional 6,462 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Revance Therapeutics by 5.1% during the 4th quarter. Rhumbline Advisers now owns 142,603 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 6,885 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Revance Therapeutics by 12.6% during the 4th quarter. Invesco Ltd. now owns 63,537 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 7,125 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Revance Therapeutics by 8.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 103,915 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 7,839 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen assumed coverage on Revance Therapeutics in a report on Wednesday, May 21st. They set a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.45.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Friday. The stock’s fifty day moving average is $3.65 and its 200 day moving average is $3.57. Revance Therapeutics, Inc. has a fifty-two week low of $2.30 and a fifty-two week high of $6.65. The firm has a market capitalization of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.